1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Lynkcell Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 LYN00101 - Ovarian Cancer, Cervical Cancer | Phase 1 | Withdrawn | Lynkcell Inc. | 2019-04-03 | 2020-03-11 |
Colorectal Neoplasms (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)